This
petition was submitted by Rhian Barrance having collected 5,717 signatures
online.
Text of Petition
We
call on the National Assembly for Wales to call for a resolution to ongoing
negotiations between NHS Wales, the All Wales Medicines Strategy Group, the
Welsh Health and Specialised Services Committee and Vertex Pharmaceuticals
regarding access to the cystic fibrosis medicine, Orkambi, as a matter of the
utmost urgency.
Additional Information
418 people in Wales have
cystic fibrosis (CF). CF is a life-shortening, inherited disorder. The median
age at death for a person with CF in 2016 was just 31 years of age. CF is
caused by mutations in the CFTR gene which result in the build-up of thick,
sticky mucus in the lungs and other organs. Gradually, this build up causes
chronic lung infections and progressive lung damage. The treatment burden for a
person with CF is high and daily life can be a struggle.
Orkambi is a precision
medicine that 40% of people in the UK with CF could benefit from. While
conventional CF treatments target the symptoms, precision medicines tackle the
underlying genetic mutations that cause the condition. Though Orkambi is not a
cure, it has been found to slow decline in lung function – the most common
cause of death for people with CF – by 42%.
In July 2016, the National
Institute of Clinical Excellence (NICE) recognised Orkambi as an ‘important
treatment.’ They were, however, unable to recommend the drug for use within the
NHS on grounds of cost effectiveness and a lack of long-term data.
In June 2017, the Cystic
Fibrosis Trust organised a day of national protest at the Senedd, Stormont,
Holyrood, Downing Street and online to demand an end to the deadlock. Since the
protests, the Welsh Health and Specialised Services Committee (WHSSC) have
presented the All Wales Medicines Strategy Group (AWMSG) with the portfolio
approach developed by the drug’s manufacturer, Vertex Pharmaceuticals.
We call on the National
Assembly for Wales to call for a resolution to these ongoing negotiations
between NHS Wales, the AWMSG, WHSSC and Vertex Pharmaceuticals as a matter of
the utmost urgency. It is essential that a fair and sustainable method of
reimbursement is found for Orkambi and for the exciting pipeline of future
treatments.
People in Wales have been
waiting too long for this transformative drug. They deserve better.
Status
This petition is currently
under consideration by the Petitions
Committee. It was first considered by the Petitions Committee on
23/01/2018.
Assembly
Constituency and Region
Further information
Business type: Amendment
Reason considered: Assembly Business;
First published: 12/12/2017
Decision due: Meeting Date by Petitions Committee